Cymbalta Bottles Recalled; 1 in 3 Older Adults Are Lonely; Walking Off Depression

Over 230,000 bottles of the antidepressant duloxetine (Cymbalta) have been recalled due to the presence of a potential carcinogen. (USA Today)

In an exploratory analysis of two phase III trials, xanomeline/trospium chloride (Cobenfy) improved cognition in patients with acute schizophrenia and clinically significant baseline cognitive impairment. (American Journal of Psychiatry)

About one in three Americans ages 50 to 80 reported loneliness or social isolation, the National Poll on Healthy Aging showed. (JAMA)

In a cohort study of adults with depressive symptoms, Black and Asian patients, older adults, and those screened via the patient portal had lower odds of receiving initial care compared with white patients, younger patients, and those with in-person visits. (JAMA Internal Medicine)

A higher daily step count was associated with fewer depressive symptoms, a meta-analysis showed. (JAMA Network Open)

Schizophrenia and major depressive disorder may increase the risk of constipation, according to a Mendelian randomization analysis. (Clinical and Experimental Gastroenterology)

San Francisco plans to add 175 more psychiatric beds, including locked beds, for people experiencing mental illness and addiction. (San Francisco Chronicle)

A fixed-dose combination of olanzapine/samidorphan (Lybalvi) maintained symptom control with a consistent safety profile in patients with schizophrenia, schizophreniform disorder, or bipolar I disorder for up to 4 years in a phase III open-label, long-term extension trial. (Journal of Clinical Psychiatry)

The American Academy of Pediatrics published a clinical report on pediatric acute-onset neuropsychiatric syndrome. (Pediatrics)

The rate of first-time attention deficit-hyperactivity disorder (ADHD) diagnoses has been rising since 2021, but only among people ages 30 and older. (New York Times)

A small randomized trial in China showed that transcutaneous auricular vagus nerve stimulation improved chronic insomnia disorder severity. (JAMA Network Open)

MindMed announced that the first-ever phase III trial of lysergide D-tartrate (LSD) is underway, testing a pharmaceutically optimized form as a potential treatment for generalized anxiety disorder. Phase IIb findings were presented earlier this year at the American Psychiatric Association annual meeting.

The American Society of Anesthesiologists released new evidence-based recommendations on strategies to reduce the risk of postoperative delirium and cognitive issues in older patients. (Anesthesiology)

The strongest dose of once-daily investigational brilaroxazine decreased Positive and Negative Syndrome Scale (PANSS) total score by 20.8 points in patients with schizophrenia at 52 weeks, said developer Reviva Pharmaceuticals.

Autism advocates are losing faith that the FDA will ban electric shock devices. (STAT)

Please enable JavaScript to view the

comments powered by Disqus.